Background Next-generation sequencing (NGS) of cell-free circulating tumor DNA (ctDNA)
enables a non-invasive option for comprehensive genomic analysis of lung cancer patients …

Pancreatic cancer (PC) is a devastating disease. Despite decades of research, resection of
the tumor is still the lone curative treatment only feasible in early stages of PC. Diagnosis is …

Introduction: The advent of genomic based precision medicine led to the implementation of
biomarker testing in metastatic non-small cell lung cancer (NSCLC) patients. Next …

Background: Genomic profiling of ctDNA has proven to be an effective alternative to repeat
invasive biopsy in patients (pts) with advanced cancers. There is also the advantage of a …

Background Molecular profiling of cell-free circulating tumor DNA (ctDNA) in patients with
advanced NSCLC has become a powerful diagnostic approach for targeted therapy …

Results 83% of subjects had at least one genomic alteration identified in plasma. Most
commonly mutated genes were TP53, KRAS and EGFR. Subjects with no detectable ctDNA …

Circulating tumor DNA (ctDNA) analysis enables minimally invasive assessment of somatic
genetic alterations for cancer patients. ctDNA analysis is quickly being incorporated into …

Molecular characterization of non-small cell lung cancer (NSCLC) has led to marked
improvements in the treatment of patients with advanced disease who harbor driver …

Advances in deep sequencing technology have led to developments in personalized
medicine. Here, we describe the implications of a recent investigation that sequenced ctDNA …

Introduction Blood-based liquid biopsies examining circulating tumour DNA (ctDNA) have
increasing applications in non-small cell lung cancer (NSCLC). Limitations in sensitivity …